Skip to main navigation
Biohaven Pharmaceutucals Biohaven Pharmaceutucals
  • About
    • Overview
    • Our People
      • Meet our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • Media
    • Top News
    • In The News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Lookup
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Program
  • Careers
    • Overview
    • #BeBiohaven
  • Contact
Search
  • About
    • Overview
    • Our People
      • Meet our CEO
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration
  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • Media
    • Top News
    • In The News
    • Media Resources
  • Investors
    • Overview
    • Press Releases
    • Events and Presentations
      • Upcoming and Recent Events
    • Financial Filings
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Lookup
    • Corporate Governance
      • Governance Documents
      • Committees
    • Contact
  • Commitment
    • Overview
    • Early Access Program
  • Careers
    • Overview
    • #BeBiohaven
  • Contact
Gaurav Munj 2022-03-04T06:42:16+00:00

Press Releases

Site - Investor Relations Nav

  • Overview
  • Press Releases
  • Events and Presentations
  • Financial Filings
  • Stock Information
  • Corporate Governance
  • Contact
    • Upcoming and Recent Events
    • Corporate Presentation
    • SEC Filings
    • Stock Quote & Chart
    • Historical Lookup
    • Governance Documents
    • Committees
March 19, 2026
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
March 2, 2026
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026

BIOHAVEN (BHVN)

Volume
Market Cap
52 Week High
52 Week Low

Minimum 15 minutes delayed. Source: LSEG

Biohaven white logo

Footer Links - Column 1

  • About
    • Overview
    • Our People
    • Board of Directors
    • Scientific Advisory Board
    • Global Collaboration

Footer Links - Column 2

  • Media
    • Top News
    • In The News
    • Media Resources
  • COMMITMENT
    • Overview
    • Early Access Programs

Footer Links - Column 3

  • Innovation
    • Pipeline
    • Innovation Engine
    • Clinical Trials at Biohaven
    • Publications
  • CAREERS
    • Overview
    • #BeBiohaven
  • CONTACT

Footer Mobile Links

  • About
  • Pipeline
  • Media
  • Investors
  • Commitment
  • Careers
  • Contact

Footer Links - Column 4

  • INVESTORS
    • Overview
    • Press Releases
    • Events and Presentations
    • Financial Filings
    • Stock Information
    • Corporate Governance
    • Contact

BHVN


LISTED


NYSE

Site - Social Media

BIOHAVEN, LTD.

©2026 Biohaven, Ltd.

  • TERMS & CONDITIONS
  • PRIVACY
  • SOCIAL
  • COOKIES